Genmab A/S (NASDAQ:GMAB) Shares Sold by Marotta Asset Management

Marotta Asset Management trimmed its stake in Genmab A/S (NASDAQ:GMAB) by 5.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 12,793 shares of the company’s stock after selling 739 shares during the quarter. Marotta Asset Management’s holdings in Genmab A/S were worth $269,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Two Sigma Advisers LP raised its position in shares of Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after buying an additional 280,900 shares during the period. Cubist Systematic Strategies LLC lifted its position in Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after buying an additional 145,689 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after acquiring an additional 103,859 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in Genmab A/S during the 2nd quarter worth $1,354,000. Finally, Natixis Advisors LLC lifted its position in Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after acquiring an additional 47,437 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Genmab A/S stock traded down $0.08 during trading hours on Friday, hitting $22.11. 249,218 shares of the stock were exchanged, compared to its average volume of 750,186. The stock has a market capitalization of $14.63 billion, a P/E ratio of 21.47, a P/E/G ratio of 0.63 and a beta of 0.97. Genmab A/S has a 12 month low of $19.85 and a 12 month high of $31.97. The business’s 50-day moving average is $21.32 and its two-hundred day moving average is $24.25.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The company had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same period in the prior year, the company earned $0.47 EPS. On average, equities analysts predict that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Redburn Atlantic started coverage on Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Wednesday. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.